Elevance Health (ELV) Is Back In The Spotlight, What Is Drawing Attention?

Elevance Health (ELV) drew fresh attention after its recent share move, with the price closing at US$388.82. Investors are weighing this healthcare insurer’s valuation against its mixed short and longer term return profile.

Recent trading has been softer, with a 7-day share price return of 2.44% down and a 90-day share price return of 6.96% lower. However, Elevance Health’s year to date share price return is 9.76% and its 1-year total shareholder return is 19.21%, so shorter term momentum looks weaker than the longer term record.

Compare Elevance Health’s recent pullback with other insurers by scanning our curated list of list of solid balance sheet and fundamentals (25 results) for ideas with similar defensive profiles.

Elevance Health looks like a solid operator with US$201.1b in revenue and US$4.96b in net income. Yet the recent pullback raises a sharper question: Are you paying a fair price for that strength today?

Most Popular Narrative: 14% Undervalued

Against Elevance Health’s last close at $388.82, the most followed narrative pegs fair value at $451.38, using a 7.3% discount rate and a detailed earnings path to 2029 to frame that gap.

Ongoing deployment of Elevance Health’s AI, analytics and digital platforms such as HealthOS and Sydney Health, including automated prior authorization and earlier visibility into medical cost trends, is expected to tighten medical cost management and support more stable net margins and earnings over time.

See why 113 investors see Elevance Health as 14% undervalued.

Result: Fair Value of $451.38 (UNDERVALUED)

Still, the Elevance Health story can be knocked off course if medical cost trends stay elevated in Medicaid and ACA plans, or if membership erosion continues.

Find out about the key risks to this Elevance Health narrative.

Next Steps

There is a sense that Elevance Health might have more potential than the recent pullback indicates. Consider acting sooner rather than later and compare the available data with your own expectations by reviewing the 4 key rewards.

Looking for more investment ideas beyond Elevance Health?

If Elevance Health has sharpened your focus on quality, do not stop here. Use the Simply Wall St screener to surface fresh, data driven ideas now.

• Target resilient balance sheets by reviewing the list of solid balance sheet and fundamentals (25 results) that combine financial strength with measured risk profiles.
• Hunt for mispriced quality by scanning the 31 high quality undervalued stocks that fit strict valuation and fundamentals filters.
• Build a cash flow focused portfolio by checking the 7 dividend fortresses that pair higher yields with disciplined payout habits.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com